Loading cancer entity…
Loading cancer entity…
Clinical trials
8,119 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,289)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07015021 | The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients(DKPD) | not yet recruiting | N/A | 72 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Jun 11, 2025 | clinicaltrials |
| NCT06940960 | JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Affiliated Hospital of Guangdong Medical University |
| 1 |
| Jun 10, 2025 |
| clinicaltrials |
| NCT05036564 | Diagnosis; Objective RespOnse; THErApy(DOROTHEA) | recruiting | N/A | 70 | IRCCS San RaffaeleOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04898647 | Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia(SLPRaresHvisc) | recruiting | N/A | 100 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06890065 | JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia | recruiting | N/A | 20 | Shenzhen Genocury Biotech Co., Ltd.INDUSTRY | 1 | May 15, 2025 | clinicaltrials |
| NCT06942507 | Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia(BRZ-WM) | not yet recruiting | N/A | 104 | Peking Union Medical College HospitalOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06946407 | Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma | recruiting | N/A | 41 | FengYan JinOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06699394 | Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis | recruiting | N/A | 20 | Peking University People's HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05956457 | PRO and Wearable Data Insights From Individuals With R/R Multiple Myeloma | recruiting | N/A | 100 | Pack HealthINDUSTRY | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06925958 | A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Histological Expression of 68Ga-NOTA-SCH001 in Patients With Multiple Myeloma | not yet recruiting | N/A | 15 | The First Affiliated Hospital of Soochow UniversityOTHER | 0 | Apr 13, 2025 | clinicaltrials |
| NCT02964858 | Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.(DOBL) | recruiting | N/A | 840 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06924424 | Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma | active not recruiting | N/A | 105 | Peking University People's HospitalOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT05945524 | Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination(ResisTec) | recruiting | N/A | 100 | University Hospital, ToulouseOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05259553 | Biomarkers in Multiple Myeloma(VESICOM) | recruiting | N/A | 70 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT06888752 | LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple Myeloma | not yet recruiting | N/A | 35 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Mar 21, 2025 | clinicaltrials |
| NCT06832267 | Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL | recruiting | N/A | 44 | Zhejiang Cancer HospitalOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06817759 | Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer | not yet recruiting | N/A | 60 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06813573 | Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma(EVOLITION) | recruiting | N/A | 50 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06787807 | Proteomic Analysis of Patients Undergoing Bariatric Surgery | not yet recruiting | N/A | 103 | Universidade Federal de PernambucoOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06783816 | A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors | recruiting | N/A | 45 | Shanxi Bethune HospitalOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06781515 | Assessment of Disease Burden in Hairy Cell Leukemia(BRAF) | recruiting | N/A | 45 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06741813 | Allo-HSCT vs ASCT in Adult T-LBL(TROPHY-NHL01) | not yet recruiting | N/A | 230 | Peking University People's HospitalOTHER | 0 | Dec 19, 2024 | clinicaltrials |
| NCT05053607 | Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab | recruiting | N/A | 50 | Pack HealthINDUSTRY | 1 | Dec 11, 2024 | clinicaltrials |
| NCT06608147 | MOLyF : Bone Marrow and Follicular Lymphoma(MOLyF) | recruiting | N/A | 200 | Rennes University HospitalOTHER | 1 | Dec 10, 2024 | clinicaltrials |
| NCT04726787 | RadiothErapy priMIng for CAR-T(REMIT) | active not recruiting | N/A | 6 | University College, LondonOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04533217 | Examination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma. | recruiting | N/A | 90 | Spine Centre of Southern DenmarkOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06697483 | Risk Stratification and MRD-driven Maintenance for MM After ASCT | recruiting | N/A | 100 | Peking University People's HospitalOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT05333367 | MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy(MORPHEE) | recruiting | N/A | 20 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06671717 | Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma | not yet recruiting | N/A | 25 | Peking University People's HospitalOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT05662540 | PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma | recruiting | N/A | 40 | Ruijin HospitalOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06594211 | Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple Myeloma | not yet recruiting | N/A | 18 | RenJi HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06478472 | Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy | recruiting | N/A | 36 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06515249 | Integrative Therapies in Multiple Myeloma | recruiting | N/A | 300 | Bnai Zion Medical CenterOTHER_GOV | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06515262 | Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM | recruiting | N/A | 10 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06472479 | LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple Myeloma | not yet recruiting | N/A | 66 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06450821 | PROSpECT-PRIOR-2-CHEMO: PRIOR Dental Intervention Before Chemo to Reduce Chemotherapy Complications | not yet recruiting | N/A | 60 | University of LeedsOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT06364033 | Biological and Clinical Efficacy of Shingrix in Patients With CLL | not yet recruiting | N/A | 312 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06376214 | Daratumumab for Patients With Light Chain Amyloidosis | recruiting | N/A | 100 | Nanjing University School of MedicineOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04144387 | Evaluation of the Impact of the Update SMM Criteria on the Natural History of SMM to Establish New Recommendations.(CARRISMM) | active not recruiting | N/A | 395 | Intergroupe Francophone du MyelomeNETWORK | 3 | Mar 6, 2024 | clinicaltrials |
| NCT06279026 | UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma | recruiting | N/A | 15 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04349358 | FCH vs FDG PET/CT in Detection of Lesions in Patients With Multiple Myeloma (MIM)(MIM) | recruiting | N/A | 38 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05444712 | Transplantation After Complete Response In Patients With T-cell Lymphoma(TRANSCRIPT) | recruiting | N/A | 204 | Hospices Civils de LyonOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05996367 | Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple Myeloma | recruiting | N/A | 50 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05970198 | Helical Tomotherapy in Multiple Myeloma | recruiting | N/A | 58 | Fuling ZhouOTHER | 1 | Aug 1, 2023 | clinicaltrials |
| NCT05298293 | Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma(EMILY) | not yet recruiting | N/A | 160 | WepromOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT05040555 | R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden | recruiting | N/A | 64 | oubai, MD/PhDOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT04824950 | Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)(CAMIL) | recruiting | N/A | 87 | Centre Henri BecquerelOTHER | 1 | Apr 1, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jun 11, 2025source: clinicaltrials